| Ytd | 80.21% | |
| 1y | 175.32% |
| Open | 83.92 | Prev Close | 83.90 | Low | 83.86 | High | 83.93 | Mkt Cap | 8.88B |
| Vol | 336.86K | Avg Vol | 3.48M | EPS | -5.13 | P/E | -16.35 | Forward P/E | -20.54 |
| Beta | 0.23 | Short Ratio | 11.14 | Inst. Own | 119.79% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-04 | 50-d Avg | 46.52 | 200-d Avg | 44.40 | 1yr Est | 82.50 |
CRNX News
Seven small-cap stocks have surged as much as 123% in early July on buyouts, FDA developments, refin
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following compan
BALA CYNWYD, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the followi
MILWAUKEE, July 21, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Crinetics (Nasdaq: CRNX) for
NEW YORK, July 15, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde an
BALA CYNWYD, Pa., July 14, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the followi
Atumelnant is a promising treatment for congenital adrenal hyperplasia that could be a key part of V
Vertex is buying Crinetics Pharmaceuticals for $10 billion. The acquisition could add up to $5 billi
Vertex Pharmaceuticals NASDAQ: VRTX said it has entered into a definitive agreement to acquire Crine
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a lo
It is getting acquired by a larger firm in the sector.
Crinetics Pharmaceuticals (NASDAQ:CRNX | CRNX Price Prediction) shares have climbed 99% just this we
NEW YORK, July 9, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Asso
The Halftime Report Final Trades featured stock picks from Bryn Talkington, Jim Lebenthal, Liz Young
Crinetics Pharmaceuticals (NASDAQ:CRNX) has outperformed the market over the past 5 years by 21.74%
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr.,
Vertex Pharmaceuticals NASDAQ: VRTX recently announced its plans to acquire Crinetics Pharmaceutical
Evercore ISI Group analyst Gavin Clark-Gartner downgrades Crinetics Pharmaceuticals (NASDAQ:CRNX)
CRINETICS PHARM (CRNX) was a big mover last session on higher-than-average trading volume. The lates
Crinetics' Palsonify was FDA-approved late last year. The company's atumelnant is currently in late
Market sentiment slightly declines as Nasdaq falls. Crinetics shares soar, Rivian shares dip. Trade
Vertex agreed to buy Crinetics for $85 per share in cash, about $10 billion in equity value. The dea
US stocks decline on Tuesday, with Nasdaq falling 0.61% and S&P 500 dropping 0.24%. Consumer sta
Gainers Crinetics Pharmaceuticals (NASDAQ:CRNX) shares moved upwards by 98.7% to $83.53 during Tues
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
Vertex to acquire CRNX for $10B, adding approved rare disease drug Palsonify and late-stage pipeline
US stocks were mixed, Nasdaq fell 1%. DigitalOcean shares rose after strong revenue growth and earni
Oppenheimer analyst Leland Gershell downgrades Crinetics Pharmaceuticals (NASDAQ:CRNX) from Outpe
US stocks traded mixed, with the Dow gaining over 200 points as healthcare shares jumped and inform
Crinetics Pharmaceuticals shares surged after Vertex Pharmaceuticals announced an agreement to acqui
Vertex to acquire Crinetics for $10 billion, adding approved acromegaly drug Palsonify and late-stag
Gainers Crinetics Pharmaceuticals (NASDAQ:CRNX) stock increased by 98.9% to $83.59 during Tuesday&#
Cantor Fitzgerald analyst Josh Schimmer downgrades Crinetics Pharmaceuticals (NASDAQ:CRNX) from O
HC Wainwright & Co. analyst Douglas Tsao downgrades Crinetics Pharmaceuticals (NASDAQ:CRNX) f
Baird analyst Brian Skorney maintains Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Outperform a
Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) rose in pre-market trading after being acquired by Vert
Gainers Vicore Pharma Holding (NASDAQ:VCRE) stock rose 149.8% to $42.47 during Monday's after-m
Crinetics Pharmaceuticals shares are trading higher in Monday's after-hours session after the co
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX),
Wall Street analysts change outlook on top names. Check analyst ratings page for all changes. Consid
UBS analyst Ashwani Verma initiates coverage on Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Bu
HC Wainwright & Co. analyst Douglas Tsao reiterates Crinetics Pharmaceuticals (NASDAQ:CRNX) w
Data from up to two years of treatment in PATHFNDR-1 and PATHFNDR-2 open-label extension studies sho
Data show investigational atumelnant drove sustained androgen reductions while enabling lowering of
Citizens analyst Jonathan Wolleben reiterates Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Mark
Evercore ISI Group analyst Maneka Mirchandaney maintains Crinetics Pharmaceuticals (NASDAQ:CRNX)
Analysts changed outlook on top names, RBC raised CC price target, DA Davidson lowered MSA target, O
Oppenheimer analyst Leland Gershell maintains Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Outp
Citizens analyst Jonathan Wolleben maintains Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Marke
Crinetics Pharmaceuticals (NASDAQ:CRNX) reported quarterly losses of $(1.23) per share which beat th